$157 Million is the total value of Flagship Ventures 2007 General Partner LLC's 4 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGIO | New | Agios Pharmaceuticals, Inc. | $92,465,000 | – | 3,860,738 | +100.0% | 58.97% | – |
| RCPT | New | Receptos, Inc. | $46,729,000 | – | 1,611,911 | +100.0% | 29.80% | – |
| TTPH | New | Tetraphase Pharmaceuticals, Inc. | $15,761,000 | – | 1,165,786 | +100.0% | 10.05% | – |
| BGMD | New | BG Medicine, Inc. | $1,835,000 | – | 1,764,286 | +100.0% | 1.17% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-02-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGIOS PHARMACEUTICALS INC | 10 | Q2 2016 | 90.4% |
| ELEVEN BIOTHERAPEUTICS INC | 9 | Q2 2016 | 21.5% |
| BG Medicine, Inc. | 8 | Q3 2015 | 1.6% |
| RENEWABLE ENERGY GROUP INC | 8 | Q2 2016 | 1.4% |
| Seres Therapeutics, Inc. | 3 | Q4 2015 | 13.8% |
| Receptos, Inc. | 2 | Q1 2014 | 29.8% |
| SELECTA BIOSCIENCES INC | 1 | Q2 2016 | 21.5% |
| Tetraphase Pharmaceuticals, Inc. | 1 | Q4 2013 | 10.1% |
View Flagship Ventures 2007 General Partner LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2019-10-31 |
| 4 | 2019-05-15 |
| 3 | 2019-05-08 |
| 4 | 2019-05-06 |
| 3 | 2019-05-01 |
| 4 | 2019-03-06 |
| 3 | 2019-02-27 |
| 13F-NT | 2017-11-03 |
| 13F-NT | 2017-08-02 |
| 13F-NT | 2017-05-10 |
View Flagship Ventures 2007 General Partner LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.